

Communication

Daniel Austin, PharmD

J Pediatr Pharmacol Ther 2024;29(2):208

DOI: 10.5863/1551-6776-29.2.208

To the Editor.—Please be advised that a typographical error was discovered in the manuscript titled “Stability Study of a Compounded Sublingual Buprenorphine Solution for Neonatal Opioid Withdrawal Syndrome,” published in the *Journal of Pediatric Pharmacology and Therapeutics* 2023;28(8):710–713.

The noted error occurs in the third sentence of the Results section on page 711 and reads “All samples retained >9% of the initial drug concentration in the HPLC analysis, as shown in Table 2.” Although this statement is factually correct, it does not properly convey experimental results as originally intended. The corrected statement should read “All samples retained >98% of the initial drug concentration in the HPLC analysis, as shown in Table 2.”

Correspondence for this erratum may be forwarded to my attention at the address shown below. We certify that the modification to the noted sentence is correct, and that we are not aware of any other errors in the manuscript. Thank you for your consideration.

Article Information

Affiliations. Lake Erie College of Osteopathic Medicine School of Pharmacy

Correspondence. Daniel Austin, PharmD;
daustin@lecom.edu

Disclosure. The author declares no conflicts or financial interest in any product or service mentioned in this letter, including grants, equipment, medications, employment, gifts, and honoraria.

Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org